Source: Eur Respir J, 54 (3) 1900224; 10.1183/13993003.00224-2019



Rating:

Share or cite this content

Citations should be made in the following way:
Sanja Stanojevic, Jenna Sykes, Anne L. Stephenson, Shawn D. Aaron, George A. Whitmore. Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis. Eur Respir J, 54 (3) 1900224; 10.1183/13993003.00224-2019

Member's Comments

No comment yet.

Related content which might interest you: Predicting five year outcomes in adults with cystic fibrosis: Developing a predictive scoring model Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 The CF-ABLE score: A 2-year evaluation of a 4-year prognostic tool Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 External validation of the French predictive model to estimate PAH survival: A REVEAL analysis Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Validated the power of terminal status criteria in the prediction of 1-year mortality in patiens with COPD Source: Virtual Congress 2020 – Epidemiology and understanding of airways diseases in primary care Year: 2020 External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Design and assessment of an automated prediction model for 30-day re-hospitalization after a COPD exacerbation using genetic algorithms Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Extent of fibrosis by high-resolution computed tomography does not improve prediction of mortality in idiopathic pulmonary fibrosis when added to a simple clinical prediction model Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Early diagnosis from newborn screening maximises survival in severe cystic fibrosis Source: ERJ Open Res, 4 (2) 00109-2017; 10.1183/23120541.00109-2017 Year: 2018 One-year follow-up for lung function and functional capacity in cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 183s Year: 2005 Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2014; 43: 1237-1239 Year: 2014 Factors predicting mortality in cystic fibrosis where lung transplantation can not be performed Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1374-1381 Year: 2015 GAP scoring system in IPF patients treated with antifibrotics: prognostic performance and 1- to 3- years mortality: a retrospective study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Idiopathic pulmonary fibrosis: independent physiologic variables in the prediction of survival Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis Year: 2007 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 A contemporary survival analysis of individuals with cystic fibrosis: a cohort study Source: Eur Respir J 2015; 45: 670-679 Year: 2015 Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients Source: Eur Respir J 2001; 18: 306-315 Year: 2001